FDA Grants Orphan Drug Status to CLR 131 for Lymphoplasmacytic Lymphoma Treatment
News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cellectar BioSciences‘ experimental therapy CLR 131 for lymphoplasmacytic lymphoma (LPL), or Waldenström’s macroglobulinemia, a rare type of ... Read more